|
hepatocellular carcinoma |
64 |
|
liver transplantation |
37 |
|
medical sciences |
28 |
|
hepatectomy |
22 |
|
liver transplant |
22 |
|
outcomes |
20 |
|
gastroenterology |
19 |
|
recurrence |
19 |
|
survival |
19 |
|
surgery |
18 |
|
cirrhosis |
17 |
|
adult |
16 |
|
gastroenterology medical sciences |
16 |
|
liver resection |
16 |
|
next-generation sequencing |
15 |
|
transarterial chemoembolization |
15 |
|
hcc |
14 |
|
liver cancer |
14 |
|
sorafenib |
14 |
|
child-pugh a |
13 |
|
liver failure |
13 |
|
portal vein |
13 |
|
blood transfusion |
12 |
|
acute flare |
11 |
|
alpps |
11 |
|
cancer staging |
11 |
|
cancer survival |
11 |
|
decompensation |
11 |
|
hepatocellular carcinoma (hcc) |
11 |
|
high-intensity focused ultrasound |
11 |
|
living donor liver transplant |
11 |
|
meld |
11 |
|
ablation |
10 |
|
acute-on-chronic liver failure |
10 |
|
bridging therapy |
10 |
|
immunotherapy |
10 |
|
living donor |
10 |
|
living donor liver transplantation |
10 |
|
molecular biology |
10 |
|
molecular pathology |
10 |
|
morbidity |
10 |
|
new technology |
10 |
|
signaling |
10 |
|
11c-acetate |
9 |
|
cancer invasion |
9 |
|
contrast ct |
9 |
|
endocrinology |
9 |
|
hifu |
9 |
|
laparoscopic liver resection |
9 |
|
milan criteria |
9 |
|
mortality |
9 |
|
non-invasive treatment |
9 |
|
pet/ct |
9 |
|
resection |
9 |
|
survival analysis |
9 |
|
acetic acid c 11 |
8 |
|
advanced cancer |
8 |
|
advanced hcc |
8 |
|
advanced hepatocellular carcinoma |
8 |
|
adverse events |
8 |
|
aged |
8 |
|
antiviral agents - adverse effects - therapeutic use |
8 |
|
bile ducts - surgery |
8 |
|
cadaver donor |
8 |
|
cancer recurrence |
8 |
|
cancer stem cells |
8 |
|
carcinoma, hepatocellular - complications/diagnosis - surgery |
8 |
|
carcinoma, hepatocellular - surgery - virology |
8 |
|
cardiac function |
8 |
|
child-pugh b |
8 |
|
colorectal cancer |
8 |
|
deceased donor liver transplantation |
8 |
|
disease severity |
8 |
|
elderly |
8 |
|
fluorodeoxyglucose f 18 |
8 |
|
gene mutation |
8 |
|
gist |
8 |
|
guanine - adverse effects - analogs and derivatives - therapeutic use |
8 |
|
hepatectomy - methods |
8 |
|
hepatitis b |
8 |
|
hepatitis b, chronic - complications - diagnosis - drug therapy - surgery |
8 |
|
liver cirrhosis - surgery - virology |
8 |
|
liver disease |
8 |
|
liver metastasis |
8 |
|
liver neoplasms - complications/diagnosis - surgery |
8 |
|
living-donor liver transplantation |
8 |
|
prevention |
8 |
|
rsk2 |
8 |
|
seroconversion (sc) |
8 |
|
stereotactic body radiation therapy |
8 |
|
thrombosis - diagnosis - etiology - surgery |
8 |
|
tki |
8 |
|
tyrosine-kinase inhibitor |
8 |
|
unresectable |
8 |
|
waiting list |
8 |
|
abdominal abscess |
7 |
|
abdominal bleeding |
7 |
|
abdominal surgery |
7 |
|
adjuvant therapy |
7 |
|
biliary anastomotic stricture |
7 |
|
body mass index |
7 |
|
cap |
7 |
|
cardiac surgery |
7 |
|
complication |
7 |
|
cytology and histology |
7 |
|
de novo hbv |
7 |
|
de novo hepatocellular carcinoma |
7 |
|
domino liver transplant |
7 |
|
entecavir |
7 |
|
experience |
7 |
|
extended criteria organ |
7 |
|
general surgery |
7 |
|
glycolysis |
7 |
|
graft-to-recipient weight ratio |
7 |
|
head of pancreas |
7 |
|
hepatitis b infection |
7 |
|
hepatitis b vaccination |
7 |
|
hypoxia |
7 |
|
icc |
7 |
|
indocyanine green clearance |
7 |
|
intrahepatic cholangiocarcinoma |
7 |
|
laparoscopy |
7 |
|
laparoscopy - statistics and numerical data |
7 |
|
limon |
7 |
|
liver biopsy |
7 |
|
liver cirrhosis |
7 |
|
long-term outcome |
7 |
|
long-term survival |
7 |
|
mafld |
7 |
|
medicine & public health |
7 |
|
metabolic syndrome |
7 |
|
model for end-stage liver disease |
7 |
|
nafld |
7 |
|
oncology medical sciences |
7 |
|
pediatric |
7 |
|
pfkfb |
7 |
|
portal vein resection |
7 |
|
prognosis |
7 |
|
ptbd |
7 |
|
pulse spectrophotometry |
7 |
|
radiofrequency ablation |
7 |
|
radiology and nuclear medicine pharmacy and pharmacology biology |
7 |
|
recurrent hcc |
7 |
|
retransplantation |
7 |
|
right liver graft |
7 |
|
right-lobe |
7 |
|
small-for-size syndrome |
7 |
|
survival outcomes |
7 |
|
systemic therapy |
7 |
|
thoracic surgery |
7 |
|
transthyretin |
7 |
|
val30ala |
7 |
|
vascular surgery |
7 |
|
vcte |
7 |
|
whipple operation |
7 |
|
acute pancreatitis |
6 |
|
adverse outcome |
6 |
|
aged, 80 and over |
6 |
|
alpha-fetoprotein |
6 |
|
anastomosis, surgical |
6 |
|
antiviral therapy |
6 |
|
artificial intelligence |
6 |
|
bile leak |
6 |
|
biliary complications |
6 |
|
biliary reconstruction |
6 |
|
biliary stricture |
6 |
|
breast cancer |
6 |
|
carcinoma, hepatocellular - diagnosis - therapy |
6 |
|
carcinoma, hepatocellular - surgery |
6 |
|
case-matched study |
6 |
|
cdk1 inhibitor |
6 |
|
cholangiocarcinoma |
6 |
|
cholangiograms |
6 |
|
cholestasis - etiology |
6 |
|
close resection margin |
6 |
|
colorectal liver metastasis |
6 |
|
complex liver resection |
6 |
|
computed tomography |
6 |
|
controlled study |
6 |
|
cytokines |
6 |
|
deceased-donor liver transplantation |
6 |
|
deep learning |
6 |
|
desmosplastic reaction |
6 |
|
diagnostic imaging |
6 |
|
donor hepatectomy |
6 |
|
duct-to-duct anastomosis |
6 |
|
ductal anomaly |
6 |
|
en-bloc resection |
6 |
|
end-stage liver disease |
6 |
|
endoscopic retrograde cholangiography |
6 |
|
endoscopic treatment |
6 |
|
erc |
6 |
|
family history |
6 |
|
graft |
6 |
|
graft survival |
6 |
|
graft-weight-to-recipient-weight ratio |
6 |
|
hepatic surgery |
6 |
|
hepaticojejunostomy |
6 |
|
hepatoblastoma |
6 |
|
hepatocellullar carconoma |
6 |
|
hepatocholangiocarcinoma |
6 |
|
hepatopancreatoduodenectomy |
6 |
|
inflammation |
6 |
|
inflow |
6 |
|
invasion |
6 |
|
keywords |
6 |
|
laparoscopic resection |
6 |
|
ldlt |
6 |
|
liver neoplasms - diagnosis - therapy |
6 |
|
liver neoplasms - surgery |
6 |
|
liver resection (lr) |
6 |
|
liver stiffness |
6 |
|
liver transplantation (lt) |
6 |
|
liver transplantation - adverse effects |
6 |
|
living |
6 |
|
living donors |
6 |
|
metastases |
6 |
|
modulation |
6 |
|
neoplasm recurrence, local - surgery |
6 |
|
nomogram |
6 |
|
outcome |
6 |
|
pdx models |
6 |
|
pediatric donor |
6 |
|
post-lt surveillance |
6 |
|
post-transplant recurrence |
6 |
|
prediction |
6 |
|
predictive model |
6 |
|
radiofrequency ablation (rfa) |
6 |
|
right liver donation |
6 |
|
right-liver |
6 |
|
risk factor |
6 |
|
ro3306 |
6 |
|
simultaneous resection |
6 |
|
size |
6 |
|
small-for-size grafts |
6 |
|
stage resection |
6 |
|
standard |
6 |
|
stereotactic body radiotherapy |
6 |
|
synchronous colorectal liver metastasis |
6 |
|
tricuspid annuloplasty |
6 |
|
tumor recurrence |
6 |
|
tumour thrombus |
6 |
|
adefovir |
5 |
|
adjuvant chemotherapy |
5 |
|
alpha-fetoprotein (afp) |
5 |
|
angioplasty - methods |
5 |
|
anterior approach |
5 |
|
antitubercular agents - pharmacokinetics - therapeutic use |
5 |
|
aspartate aminotransferase |
5 |
|
augmented reality |
5 |
|
biliary obstruction |
5 |
|
blunt trauma |
5 |
|
cancer stem cell |
5 |
|
chemosensitization |
5 |
|
complications |
5 |
|
cyclin d1 |
5 |
|
deceased-donor liver re-transplantation |
5 |
|
dose-response relationship, drug |
5 |
|
double bypass |
5 |
|
dual portal vein |
5 |
|
graft failure |
5 |
|
hepatic artery thrombosis |
5 |
|
hepatic malignancy |
5 |
|
hepatitis b virus |
5 |
|
laparoscopic hepatectomy |
5 |
|
live donor liver transplantation |
5 |
|
liver laceration |
5 |
|
liver remnant |
5 |
|
liver transplantation - methods |
5 |
|
liver trauma |
5 |
|
living-donor liver re-transplantation |
5 |
|
macrophage polarization |
5 |
|
malignancy |
5 |
|
meta-analysis |
5 |
|
metal stent |
5 |
|
multiple injuries |
5 |
|
non-operative management |
5 |
|
oncological outcomes |
5 |
|
opportunistic infections - prevention and control |
5 |
|
pancreatic cancer |
5 |
|
pancreaticoduodenectomy |
5 |
|
pancreaticojejunostomy |
5 |
|
pancreatoduodenectomy |
5 |
|
pancreatogastrostomy |
5 |
|
paraganglioma |
5 |
|
penetrative trauma |
5 |
|
portal vein - anatomy and histology - surgery |
5 |
|
portal vein reconstruction |
5 |
|
post-hepatectomy |
5 |
|
post-operative complication |
5 |
|
predicting scoring system |
5 |
|
pretreatment extent of disease |
5 |
|
relapse |
5 |
|
remnant |
5 |
|
risk stratification |
5 |
|
single-cell rna sequencing |
5 |
|
smad inhibitor |
5 |
|
smad2/3/smad4 |
5 |
|
surveillance |
5 |
|
tissue and organ harvesting - methods |
5 |
|
tuberculosis |
5 |
|
tuberculosis - diagnosis - drug therapy - transmission |
5 |
|
tumor heterogeneity |
5 |
|
vaccination |
5 |
|
afp |
4 |
|
antibody-mediated rejection |
4 |
|
associating liver partition and portal vein ligation for staged hepatectomy |
4 |
|
bilirubin level |
4 |
|
carcinoma, hepatocellular - mortality - surgery |
4 |
|
carcinoma, hepatocellular - pathology - surgery |
4 |
|
carcinoma, hepatocellular - pathology - therapy |
4 |
|
catheter ablation - methods |
4 |
|
checkpoint inhibitor |
4 |
|
chemotherapy |
4 |
|
cholangiocarcinoma - pathology - surgery |
4 |
|
cholesterol |
4 |
|
combined hcc-cc |
4 |
|
complex liver surgery |
4 |
|
deceased donor liver transplant |
4 |
|
disease-free survival |
4 |
|
dyslipidemia |
4 |
|
emergency laparoscopic cholecystectomy |
4 |
|
ercp |
4 |
|
fasting glucose |
4 |
|
grafts |
4 |
|
hepatectom |
4 |
|
hepatectomy - statistics and numerical data |
4 |
|
hepatitis |
4 |
|
hepatopancreaticobiliary surgery |
4 |
|
hilar cholangiocarcinoma |
4 |
|
icg |
4 |
|
icg fluorescence |
4 |
|
indocyanine green |
4 |
|
kidney transplantation |
4 |
|
left lobe graft |
4 |
|
lipoprotein |
4 |
|
liver neoplasms - mortality - surgery |
4 |
|
liver neoplasms - pathology - surgery |
4 |
|
liver neoplasms - pathology - therapy |
4 |
|
mixed tumor, malignant - pathology - surgery |
4 |
|
open conversion |
4 |
|
orthotopic liver transplantation |
4 |
|
preoperative biliary drainage |
4 |
|
radiosurgery |
4 |
|
right lobe |
4 |
|
right lobe graft |
4 |
|
ruptured hepatocellular carcinoma |
4 |
|
small for size liver graft |
4 |
|
stereotactic ablative radiation therapy |
4 |
|
stereotactic radiation therapy |
4 |
|
survivor |
4 |
|
technique |
4 |
|
transplants |
4 |
|
triglyceride |
4 |
|
vascular reconstruction |
4 |
|
vascular resection |
4 |
|
aclf |
3 |
|
adenocarcinoma - mortality - pathology - surgery |
3 |
|
associating liver partition and portal vein ligation for stage hepatectomy |
3 |
|
biomarker |
3 |
|
cancer |
3 |
|
colectomy - methods |
3 |
|
colorectal neoplasms - mortality - pathology - surgery |
3 |
|
compensatory sweating |
3 |
|
conversion |
3 |
|
covid-19 |
3 |
|
hepatic resection |
3 |
|
hepatitis b immune globulin |
3 |
|
immunoglobulin |
3 |
|
in-situ split |
3 |
|
inferior vena cava |
3 |
|
intensity |
3 |
|
laparoscopic colectomy |
3 |
|
laparotomy - statistics and numerical data |
3 |
|
leiomyosarcoma |
3 |
|
non-colorectal liver metastasis |
3 |
|
primary hyperhidrosis |
3 |
|
radiotherapy |
3 |
|
resection margin |
3 |
|
soft tissue sarcoma |
3 |
|
systemic immunity |
3 |
|
tenofovir |
3 |
|
thoracoscopic sympathectomy |
3 |
|
vena caval tumor |
3 |
|
acute kidney injury |
2 |
|
acute liver failure and scute liver failure |
2 |
|
acute on chronic liver failure |
2 |
|
anamnesis |
2 |
|
anatomic landmark |
2 |
|
anatomic liver resection |
2 |
|
antineoplastic agents |
2 |
|
ascites |
2 |
|
blood clotting |
2 |
|
case report |
2 |
|
chronic hepatitis b |
2 |
|
chronic liver disease |
2 |
|
colectomy |
2 |
|
colorectal neoplasms |
2 |
|
cytoreductive surgical procedures |
2 |
|
golden window |
2 |
|
indocyanine green (icg) clearance |
2 |
|
liver anatomy |
2 |
|
liver function reserve |
2 |
|
liver metastases |
2 |
|
liver neoplasms |
2 |
|
liver neoplasms/secondary |
2 |
|
liver neoplasms/surgery |
2 |
|
magnetic resonance imaging |
2 |
|
minimally invasive liver surgery |
2 |
|
modelling |
2 |
|
multiple organ failure |
2 |
|
neuroendocrine tumor |
2 |
|
neuroendocrine tumors/therapy |
2 |
|
perintoneal neoplasms |
2 |
|
piro |
2 |
|
portal vein embolization |
2 |
|
radiomics |
2 |
|
sirs |
2 |
|
surgical resection |
2 |
|
trans-arterial chemoembolization |
2 |
|
transplant oncology |
2 |
|
tumor burden score |
2 |
|
acrylic resins - adverse effects |
1 |
|
asia |
1 |
|
associating liver partition and portal vein ligation for staged heaptectomy |
1 |
|
associating liver partition with portal vein ligation for staged hepatectomy |
1 |
|
biopsy, fine-needle |
1 |
|
breast |
1 |
|
breast diseases - etiology - pathology |
1 |
|
chronic hepatitis |
1 |
|
colorectal liver metastases |
1 |
|
consensus development conference |
1 |
|
conversion therapy |
1 |
|
cytology |
1 |
|
donor |
1 |
|
downstaging |
1 |
|
endosonography |
1 |
|
equipoise |
1 |
|
ethics |
1 |
|
expanding donor pool |
1 |
|
expert liver surgeons |
1 |
|
extended surgery |
1 |
|
gallbladder cancer |
1 |
|
high model for end-stage liver disease |
1 |
|
laparoscopic liver surgery |
1 |
|
laparoscopic major hepatectomy |
1 |
|
liver |
1 |
|
mammaplasty - adverse effects - methods |
1 |
|
mammoplasty |
1 |
|
minimally invasive donor surgery |
1 |
|
minimally invasive liver resection |
1 |
|
pancreatic neoplasms |
1 |
|
pancreatic pseudocyst |
1 |
|
patient selection |
1 |
|
polyacrylamide gel |
1 |
|
review |
1 |
|
robotic liver surgery |
1 |
|
surgical outcomes |
1 |
|
technical modifications |
1 |
|
transplant |
1 |
|
two-stage hepatectomy |
1 |
|
variability of treatment strategies |
1 |
